https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48900 Wed 19 Apr 2023 16:40:13 AEST ]]> Short-course radiation plus temozolomide in elderly patients with glioblastoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34579 Wed 09 Mar 2022 16:00:51 AEDT ]]> Vasculogenic Mimicry Occurs at Low Levels in Primary and Recurrent Glioblastoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54632 Wed 06 Mar 2024 10:59:47 AEDT ]]> DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48767 Wed 05 Apr 2023 13:55:36 AEST ]]> ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54816 Thu 14 Mar 2024 14:38:44 AEDT ]]> Exploring positive survivorship experiences of indigenous Australian cancer patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32799 Thu 09 Dec 2021 11:02:52 AEDT ]]> The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline' https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27289 Sat 24 Mar 2018 07:40:21 AEDT ]]> Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28464 Sat 24 Mar 2018 07:39:34 AEDT ]]> Percutaneous CT-guided thermal ablation as salvage therapy for recurrent non-small cell lung cancer after external beam radiotherapy: a retrospective study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27987 30 mm 14 months (p = 0.20). Recurrence rates reduced from 50% after initial ablation to 20% with a second ablation. Complication rate for pneumothorax requiring intervention was 17%. Conclusion: Both RFA and MWA ablation prolonged local tumour control with minimal morbidity in this study group of recurrent NSCLC after radiotherapy.]]> Sat 24 Mar 2018 07:38:42 AEDT ]]> The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27417 Sat 24 Mar 2018 07:35:24 AEDT ]]> Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26160 Mon 22 Jul 2019 13:58:34 AEST ]]> Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44180 Mon 10 Oct 2022 10:34:22 AEDT ]]> Comparison between [⁶⁸Ga]Ga-PSMA-617 and [¹⁸F]FET PET as Imaging Biomarkers in Adult Recurrent Glioblastoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55074 Mon 08 Apr 2024 14:10:37 AEST ]]> A novel semiautomated method for background activity and biological tumour volume definition to improve standardisation of ¹⁸F-FET PET imaging in glioblastoma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47450 Fri 20 Jan 2023 16:21:31 AEDT ]]> Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51740 Fri 15 Sep 2023 18:14:17 AEST ]]>